| 51 |
26572910 | Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods. | 2015 Dec |
1 |
| 52 |
27057293 | Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. | 2015 Oct-Dec |
1 |
| 53 |
28834677 | Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone. | 2015 Sep |
2 |
| 54 |
24297687 | Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). | 2014 Jan |
1 |
| 55 |
24486397 | Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers. | 2014 Mar 5 |
1 |
| 56 |
24493871 | Aldosterone synthase inhibitors in cardiovascular and renal diseases. | 2014 Feb |
1 |
| 57 |
24713303 | Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia. | 2014 May 9 |
1 |
| 58 |
25016400 | Comparison of agents that affect aldosterone action. | 2014 May |
1 |
| 59 |
25016401 | Aldosterone blockade in chronic kidney disease. | 2014 May |
1 |
| 60 |
23006216 | Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males. | 2013 Mar |
1 |
| 61 |
23171954 | Mineralocorticoid receptor antagonists: their use and differentiation in Japan. | 2013 Mar |
1 |
| 62 |
23333184 | Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications. | 2013 Apr |
1 |
| 63 |
23349535 | Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? | 2013 Feb |
1 |
| 64 |
23456826 | Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion. | 2013 Jul |
2 |
| 65 |
23582279 | Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. | 2013 Dec |
1 |
| 66 |
23661677 | Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. | 2013 Jul |
1 |
| 67 |
23719402 | Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. | 2013 Nov-Dec |
1 |
| 68 |
23740451 | Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. | 2013 May |
1 |
| 69 |
23838006 | Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain. | 2013 Nov |
1 |
| 70 |
23881669 | Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. | 2013 Sep |
1 |
| 71 |
23888997 | Mineralocorticoid receptor and cardiac arrhythmia. | 2013 Dec |
4 |
| 72 |
24120080 | Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. | 2013 Oct 25 |
1 |
| 73 |
24133375 | Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. | 2013 Oct 4 |
1 |
| 74 |
24231917 | Management of patients with resistant hypertension: current treatment options. | 2013 Oct 22 |
1 |
| 75 |
22205191 | Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. | 2012 Feb |
2 |
| 76 |
22214629 | Eplerenone improved hypokalemia in a patient with Gitelman's syndrome. | 2012 |
1 |
| 77 |
22411952 | Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. | 2012 May 1 |
1 |
| 78 |
22608985 | Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. | 2012 Jul 1 |
1 |
| 79 |
22684104 | Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. | 2012 Jul |
1 |
| 80 |
22717248 | Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. | 2012 Nov-Dec |
1 |
| 81 |
22778046 | Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. | 2012 Oct |
1 |
| 82 |
22791416 | Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. | 2012 Aug |
2 |
| 83 |
23023156 | Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. | 2012 Nov |
2 |
| 84 |
21144811 | [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications]. | 2011 Jun |
1 |
| 85 |
21186336 | Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. | 2011 |
1 |
| 86 |
21190955 | Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney. | 2011 Feb |
2 |
| 87 |
21207206 | Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. | 2011 Mar |
1 |
| 88 |
21731887 | Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. | 2011 |
1 |
| 89 |
21896143 | Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. | 2011 Sep |
1 |
| 90 |
22032706 | Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. | 2011 Nov 1 |
2 |
| 91 |
20535129 | Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin. | 2010 Oct |
2 |
| 92 |
20625290 | Aldosterone blockade in chronic kidney disease: can it improve outcome? | 2010 Sep |
1 |
| 93 |
18040710 | Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of L-type calcium currents in cultured neonatal cardiomyocytes. | 2008 May |
1 |
| 94 |
18084345 | Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. | 2008 Jan |
2 |
| 95 |
18555797 | Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium. | 2008 Aug 22 |
1 |
| 96 |
18585409 | Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. | 2008 Nov 29 |
2 |
| 97 |
18729003 | Mineralocorticoid receptor antagonists and endothelial function. | 2008 Sep |
2 |
| 98 |
17596522 | Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. | 2007 Sep |
2 |
| 99 |
17645055 | [Aldosterone receptor antagonists]. | 2007 May 30 |
1 |
| 100 |
17827916 | [Molecular mechanism of cardiovascular damage induced by aldosterone]. | 2007 Sep |
1 |